

Filgrastim Biosimilars Global Market 2024 To Reach \$1.66 Billion By 2028 At Rate Of 10.7%

*The Business Research Company's
Filgrastim Biosimilars Global Market
Report 2024 – Market Size, Trends, And
Global Forecast 2024-2033*

LANDON, GREATER LANDON, UK, July 19, 2024 /EINPresswire.com/ -- The filgrastim biosimilars market has experienced robust growth in recent years, expanding from \$1.02 billion in

2023 to \$1.1 billion in 2024 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to emerging markets growth, increase in patent expiration, government initiatives, increased healthcare expenditure, low cost of biosimilars, strong pipeline of drugs and increase in biopharmaceutical r&d expenditure.



The Business
Research Company

Filgrastim Biosimilars Global Market Report 2024 –
Market Size, Trends, And Global Forecast 2024-2033



You Can Now Pre Order
Your Report To Get A Swift
Deliver With All Your Needs
"

*The Business Research
Company*

Strong Future Growth Anticipated

The filgrastim biosimilars market is projected to continue its strong growth, reaching \$1.66 billion in 2028 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to aging population, increase in healthcare access.

Explore Comprehensive Insights Into The Global Filgrastim

Biosimilars Market With A Detailed Sample Report:

https://www.thebusinessresearchcompany.com/sample_request?id=4016&type=smp

Growth Driver Of The Filgrastim Biosimilars Market

The increasing prevalence of neutropenia is expected to propel the growth of the filgrastim biosimilar market going forward. Neutropenia refers to a condition where the body does not have enough neutrophils, which are an important type of white blood cell that fights infections. Filgrastim biosimilars work by stimulating the production of neutrophils in the bone marrow, which increases the neutrophil count and helps fight infections.

Make Your Report Purchase Here And Explore The Whole Industry's Data As Well:

<https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilar-global-market-report>

Major Players And Market Trends

Key players in the filgrastim biosimilars market include Teva Pharmaceutical Industries Ltd., Novartis International AG, Biocon Limited, Intas Biopharmaceuticals, Dr. Reddy's Laboratories. Major companies operating in the filgrastim biosimilar market are developing innovative products with advanced technologies such as recombinant DNA technology to produce biosimilars. Recombinant DNA technology is a process that involves the creation of hybrid or chimeric DNA by inserting a foreign sequence into the DNA of an organism.

Segments:

- 1) By Type Of Manufacturing: In-House Manufacturing, Contract Manufacturing organization
- 2) By Application: Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Other Applications
- 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Geographical Insights: North America Leading The Market

North America was the largest region in the filgrastim biosimilar markets market in 2023. The Middle East is expected to be the fastest growing region in the global filgrastim biosimilar markets market during the forecast period. The regions covered in the filgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Filgrastim Biosimilars Market Definition

Filgrastim biosimilars refer to a biosimilar that is intended to treat patients who suffer bone marrow damage from extremely high radiation doses in a manner similar to how it helps cancer patients by stimulating the formation of white blood cells, making patients less susceptible to infections.

[Filgrastim Biosimilars Global Market Report 2024](#) from The Business Research Company covers the following information:

- Market size data for the forecast period: Historical and Future
- Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
- Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.

[The Filgrastim Biosimilars Global Market Report 2024](#) by The Business Research Company is the most comprehensive report that provides insights on filgrastim biosimilars market size, filgrastim biosimilars market drivers and trends, filgrastim biosimilars market major players, filgrastim biosimilars competitors' revenues, filgrastim biosimilars market positioning, and

filgrastim biosimilars market growth across geographies. The filgrastim biosimilars market report helps you gain in-depth insights into opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company:

Neutropenia Biologic Drug Treatment Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/neutropenia-biologic-drug-treatments-global-market-report>

G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/g-csf-global-market-report>

Pegfilgrastim Biosimilars Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report>

[About The Business Research Company](#)

The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database

The Global Market Model, The Business Research Company's flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

Contact Information

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/728825077>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.